Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 70, No 2 (2020)
Research paper (original)
Published online: 2020-04-07
View PDF Download PDF file
Get Citation

Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients

Dominika Hempel12, Robert Chrenowicz34, Tomasz Filipowski2, Marek Z. Wojtukiewicz1, Ewa Sierko12
DOI: 10.5603/NJO.2020.0012
·
Nowotwory. Journal of Oncology 2020;70(2):47-53.
Affiliations
  1. Department of Oncology, Medical University of Bialystok, Poland
  2. Department of Radiotherapy, Comprehensive Cancer Center in Bialystok, Poland
  3. Department of Physics, Comprehensive Cancer Center in Bialystok, Poland
  4. Department of Physics, University of Bialystok, Poland

open access

Vol 70, No 2 (2020)
Original article
Published online: 2020-04-07

Abstract

Introduction: To assess the dose received by testes during XVI-guided IMRT in prostate cancer patients (PCPs).

Material and methods: Testes dose was calculated in 56 PCPs who underwent definitive IMRT using 6 MV or 15 MV photon energies. The dose was measured by thermoluminescent dosimeters (TLDs) MTS-N attached to the scrotum during the first three fractions of IMRT. Testicular concomitant exposure from XVI was measured using a PTW DIADOS E diagnostic dosimeter in ten randomly chosen patients.

Results: The mean and standard deviation values of the average calculated testes dose was 123 ± 117 cGy comprising 1.6% of the prescribed total irradiation dose (Dt). A testicular dose measured by TLDs was 303 ± 110.5 cGy (4% of Dt) and depended on the distance from isocenter to testes (r = –0.8). From one XVI scan, the detected testicular mean dose was 4.3 mGy. Mean XVI scan numbers for all patients was 10.4 so mean concomitant dose in testes was 44.7 mGy (0.06% of Dt).

Conclusions: Testicular dose may be significant in the aspect of fertility during IMRT in PCPs. Kilovoltage XVI-contributed dose to testes seems to be clinically negligible.

Abstract

Introduction: To assess the dose received by testes during XVI-guided IMRT in prostate cancer patients (PCPs).

Material and methods: Testes dose was calculated in 56 PCPs who underwent definitive IMRT using 6 MV or 15 MV photon energies. The dose was measured by thermoluminescent dosimeters (TLDs) MTS-N attached to the scrotum during the first three fractions of IMRT. Testicular concomitant exposure from XVI was measured using a PTW DIADOS E diagnostic dosimeter in ten randomly chosen patients.

Results: The mean and standard deviation values of the average calculated testes dose was 123 ± 117 cGy comprising 1.6% of the prescribed total irradiation dose (Dt). A testicular dose measured by TLDs was 303 ± 110.5 cGy (4% of Dt) and depended on the distance from isocenter to testes (r = –0.8). From one XVI scan, the detected testicular mean dose was 4.3 mGy. Mean XVI scan numbers for all patients was 10.4 so mean concomitant dose in testes was 44.7 mGy (0.06% of Dt).

Conclusions: Testicular dose may be significant in the aspect of fertility during IMRT in PCPs. Kilovoltage XVI-contributed dose to testes seems to be clinically negligible.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

prostate cancer; testes doses; XVI; IMRT

About this article
Title

Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients

Journal

Nowotwory. Journal of Oncology

Issue

Vol 70, No 2 (2020)

Article type

Research paper (original)

Pages

47-53

Published online

2020-04-07

Page views

354

Article views/downloads

502

DOI

10.5603/NJO.2020.0012

Bibliographic record

Nowotwory. Journal of Oncology 2020;70(2):47-53.

Keywords

prostate cancer
testes doses
XVI
IMRT

Authors

Dominika Hempel
Robert Chrenowicz
Tomasz Filipowski
Marek Z. Wojtukiewicz
Ewa Sierko

References (52)
  1. National Cancer Registry (2014). http://onkologia.org.pl.
  2. Boehmer D, Badakhshi H, Kuschke W, et al. Testicular Dose in Prostate Cancer Radiotherapy. Strahlenther Onkol. 2005; 181(3): 179–184.
    CrossRef
  3. Candela-Juan C, Perez-Calatayud J, Ballester F, et al. Calculated organ doses using Monte Carlo simulations in a reference male phantom undergoing HDR brachytherapy applied to localized prostate carcinoma. Med Phys. 2013; 40(3): 033901.
    CrossRefPubMed
  4. Wallis CJD, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016; 352: i851.
    CrossRefPubMed
  5. Vora S, Wong W, Schild S, et al. Outcome and Toxicity for Patients Treated with Intensity Modulated Radiation Therapy for Localized Prostate Cancer. J Urol. 2013; 190(2): 521–526.
    CrossRef
  6. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017; 71(4): 618–629.
    CrossRefPubMed
  7. Shalet SM. Effect of irradiation treatment on gonadal function in men treated for germ cell cancer. Eur Urol. 1993; 23(1): 148–151; discussion 152.
    CrossRefPubMed
  8. Lee SH, Shin CHo. Reduced male fertility in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2013; 18(4): 168–172.
    CrossRefPubMed
  9. Vassilakopoulou M, Boostandoost E, Papaxoinis G, et al. Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions. Crit Rev Oncol Hematol. 2016; 97: 328–334.
    CrossRefPubMed
  10. Grewenig A, Schuler N, Rübe CE. Persistent DNA Damage in Spermatogonial Stem Cells After Fractionated Low-Dose Irradiation of Testicular Tissue. Int J Radiat Oncol Biol Phys. 2015; 92(5): 1123–1131.
    CrossRefPubMed
  11. Son Y, Heo K, Bae MJ, et al. Injury to the blood-testis barrier after low-dose-rate chronic radiation exposure in mice. Radiat Prot Dosimetry. 2015; 167(1-3): 316–320.
    CrossRefPubMed
  12. Demir A, Karadag MA, Cecen K, et al. Effects of testosterone treatment on recovery of rat spermatogenesis after irradiation. J Pak Med Assoc. 2015; 65(3): 300–305.
    PubMed
  13. Sujenthiran A, Nossiter J, Charman SC, et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017; 99(5): 1253–1260.
    CrossRefPubMed
  14. Pollack A, Abramowitz MC. Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer. J Clin Oncol. 2016; 34(15): 1715–1717.
    CrossRefPubMed
  15. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol. 2008; 53(13): R193–R241.
    CrossRefPubMed
  16. Singhal MK, Kapoor A, Singh D, et al. Scattered radiation to gonads: role of testicular shielding for para-aortic and homolateral illiac nodal radiotherapy. J Egypt Natl Canc Inst. 2014; 26(2): 99–101.
    CrossRefPubMed
  17. Halg RA, Besserer J, Schneider U. Systematic measurements of whole-body imaging dose distributions in image-guided radiation therapy. Med Phys. 2012; 39(12): 7650–7661.
    CrossRefPubMed
  18. Hess CB, Thompson HM, Benedict SH, et al. Exposure Risks Among Children Undergoing Radiation Therapy: Considerations in the Era of Image Guided Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 94(5): 978–992.
    CrossRefPubMed
  19. Fricker K, Thompson C, Meyer J. Assessment of concomitant testicular dose with radiochromic film. Australas Phys Eng Sci Med. 2013; 36(3): 269–277.
    CrossRefPubMed
  20. Loutfi-Krauss B, Köhn J, Blümer N, et al. Effect of dose reduction on image registration and image quality for cone-beam CT in radiotherapy. Strahlenther Onkol. 2015; 191(2): 192–200.
    CrossRefPubMed
  21. Amies CJ, Mameghan H, Rose A, et al. Testicular doses in definitive radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995; 32(3): 839–846.
    CrossRefPubMed
  22. Fraass BA, Kinsella TJ, Harrington FS, et al. Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield. Int J Radiat Oncol Biol Phys. 1985; 11(3): 609–615.
    CrossRefPubMed
  23. Koshy M, Paulino AC, Marcus RB, et al. Extra-target doses in children receiving multileaf collimator (MLC) based intensity modulated radiation therapy (IMRT). Pediatr Blood Cancer. 2004; 42(7): 626–630.
    CrossRefPubMed
  24. Kinsella TJ, Trivette G, Rowland J, et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin's disease. J Clin Oncol. 1989; 7(6): 718–724.
    CrossRefPubMed
  25. Tosi G, Torresin A, Agosteo S, et al. Neutron measurements around medical electron accelerators by active and passive detection techniques. Med Phys. 1991; 18(1): 54–60.
    CrossRefPubMed
  26. Kry SF, Salehpour M, Titt U, et al. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy. Radiother Oncol. 2009; 91(1): 132–137.
    CrossRefPubMed
  27. Izard MA. Leydig cell function and radiation: a review of the literature. Radiother Oncol. 1995; 34(1): 1–8.
    CrossRefPubMed
  28. Daniell HW, Clark JC, Pereira SE, et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer. 2001; 91(10): 1889–1895.
    CrossRefPubMed
  29. Daniell HW, Tam EW. Testicular atrophy in therapeutic orchiectomy specimens from men with prostate carcinoma: association with prior prostate bed radiation and older age. Cancer. 1998; 83(6): 1174–1179.
    CrossRefPubMed
  30. Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol. 1986; 135(4): 726–727.
    CrossRefPubMed
  31. Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997; 39(1): 85–89.
    CrossRefPubMed
  32. King CR, Lo A, Kapp DS. Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys. 2009; 73(2): 636–637; author reply 637.
    CrossRefPubMed
  33. Joosten A, Bochud F, Baechler S, et al. Variability of a peripheral dose among various linac geometries for second cancer risk assessment. Phys Med Biol. 2011; 56(16): 5131–5151.
    CrossRefPubMed
  34. Howell RM, Hertel NE, Wang Z, et al. Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies. Med Phys. 2006; 33(2): 360–368.
    CrossRefPubMed
  35. Klein EE, Maserang B, Wood R, et al. Peripheral doses from pediatric IMRT. Med Phys. 2006; 33(7): 2525–2531.
    CrossRefPubMed
  36. Mansur DB, Klein EE, Maserang BP. Measured peripheral dose in pediatric radiation therapy: a comparison of intensity-modulated and conformal techniques. Radiother Oncol. 2007; 82(2): 179–184.
    CrossRefPubMed
  37. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001; 51(4): 880–914.
    CrossRefPubMed
  38. Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys. 1997; 38(3): 667–672.
    CrossRefPubMed
  39. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol. 1999; 53(3): 199–203.
    CrossRefPubMed
  40. Wang B, Xu XG. Measurements of non-target organ doses using MOSFET dosemeters for selected IMRT and 3D CRT radiation treatment procedures. Radiat Prot Dosimetry. 2008; 128(3): 336–342.
    CrossRefPubMed
  41. Deng J, Chen Z, Yu JB, et al. Testicular doses in image-guided radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82(1): e39–e47.
    CrossRefPubMed
  42. Martin JM, Handorf EA, Price RA, et al. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Med Dosim. 2015; 40(3): 186–189.
    CrossRefPubMed
  43. van der Giessen PH. Calculation and measurement of the dose at points outside the primary beam for photon energies of 6, 10, and 23 MV. Int J Radiat Oncol Biol Phys. 1994; 30(5): 1239–1246.
    CrossRefPubMed
  44. King CR, Maxim PG, Hsu A, et al. Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys. 2010; 77(2): 484–489.
    CrossRefPubMed
  45. King CR, Kapp DS. To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol. 2009; 27(36): 6076–6078.
    CrossRefPubMed
  46. Buchli C, Al Abani M, Ahlberg M, et al. Assessment of testicular dose during preoperative radiotherapy for rectal cancer. Acta Oncol. 2016; 55(4): 496–501.
    CrossRefPubMed
  47. Kase K, Svensson G, Wolbarst A, et al. Measurements of dose from secondary radiation outside a treatment field. Int J Radiat Oncol Biol Phys. 1983; 9(8): 1177–1183.
    CrossRef
  48. Bednarz B, Hancox C, Xu XG. Calculated organ doses from selected prostate treatment plans using Monte Carlo simulations and an anatomically realistic computational phantom. Phys Med Biol. 2009; 54(17): 5271–5286.
    CrossRefPubMed
  49. Bakkal BH, Vural T, Elmas O, et al. Effect of treatment position and radiotherapy planning on testicular dose in patients with rectal carcinoma. J Cancer Res Ther. 2014; 10(3): 558–562.
    CrossRefPubMed
  50. Matsumoto Y, Umezu Y, Fujibuchi T, et al. [Verification of the protective effect of a testicular shield in postoperative radiotherapy for seminoma]. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2014; 70(9): 883–887.
    CrossRefPubMed
  51. Schneider U, Hälg R, Besserer J. Concept for quantifying the dose from image guided radiotherapy. Radiat Oncol. 2015; 10: 188.
    CrossRefPubMed
  52. Hyer DE, Serago CF, Kim S, et al. An organ and effective dose study of XVI and OBI cone-beam CT systems. J Appl Clin Med Phys. 2010; 11(2): 3183.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl